Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,991 stories, page 428 of 684

Advanced search

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Is West Pharmaceutical Services Inc (WST) a Bargain After 7.7% D

GuruFocusOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

US judge says Biden-era restrictions on prescribing abortion drug are unlawful

WTVBOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Edesa Biotech, Inc. Revenue Breakdown – NASDAQ:EDSA

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers recommend relaxing US rules on compounding peptides

ReutersOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Vytrus Biotech SA Revenue Breakdown – TRADEGATE:V5P

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Veraxa Biotech Shareholders Approve All Proposals At Extraordinary General Meeting, Strengthening Strategic Flexibility For Future Growth

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Amgen submits new data to challenge FDA's proposal to withdraw Tavneos

ReutersOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugs

NBC NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition

Time MagazineOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

A U.S. review panel recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialized pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns. | via ANC 24/7 Full

facebook.comOriginal source

🌍Jul 25discoverynews.google.comTier 2 · Trade media

Amgen sheds around 40 staffers as struggles mount

Fierce BiotechOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors

MarketWatchOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Fierce Biotech hires Russo as a reporter

Talking Biz NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Lilly's triple agonist just became its most powerful obesity drug yet

Drug Discovery NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Veraxa Biotech shareholders approve governance changes

Investing.comOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers say six popular peptides can be compounded. Here are the issues they considered.

MarketWatchOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Revenue Breakdown – TWSE:1762

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Fugitive wanted for sexual assault allegedly spent 20 years on the run, lived as biotech executive

True Crime NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

AHN-GOOK PHARMACEUTICAL Co., Ltd. Revenue Breakdown – KRX:001540

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Arcus: 'Buy' Casdatifan Late-Stage ccRCC Advancement And 1st-Line Expansions (NYSE:RCUS)

Seeking AlphaOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Sartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%

simplywall.stOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Sartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%

simplywall.stOriginal source

🌍Jul 25Researchuab.eduTier 2 · Direct publisher

Bulgarella to serve on governing board of nation’s leading academic medicine association

University of Alabama at BirminghamOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Ono Pharmaceutical Co., Ltd. Unsponsored ADR Revenue Breakdown – MUN:ON40

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Legend Biotech Shares Fall After UBS Downgrade

MoomooOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Binh Dinh Pharmaceutical & Medical Equipment JSC Revenue Breakdown – HOSE:DBD

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers recommend against the first unapproved peptide on second day of meeting

whbl.comOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of NKGen Biotech Inc. – OTC:NKGN

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBITDA forward of NKGen Biotech Inc. – OTC:NKGN

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers recommend against the first unapproved peptide on second day of meeting

WTVBOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGN

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Price to book forward of NKGen Biotech Inc. – OTC:NKGN

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers recommend against the first unapproved peptide on second day of meeting

Y100 WNCYOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer

Yahoo FinanceOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Federal Judge Rules That FDA’s Mifepristone Restrictions Are Excessive, Unscientific and Unlawful

Talking Points MemoOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA panel narrowly backs peptide drug touted by Joe Rogan and other influencers

WDBJ7Original source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

EASTGATE BIOTECH CORP Revenue Breakdown – OTC:ETBI

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

DHG Pharmaceutical Joint Stock Company Revenue Breakdown – HOSE:DHG

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

What is Driving Jupiter Neurosciences' Recent Stock Volatility

Kavout | AIOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

US judge says Biden-era restrictions on prescribing abortion drug are unlawful

SRN NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA approves Tylenol with Naproxen OTC

Drug Store NewsOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest

Kavout | AIOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA advisers dismiss safety warnings, back four peptide treatments

Medical XpressOriginal source

🌍Jul 25discoverynews.google.comTier 2 · Trade media

Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback

Fierce PharmaOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Aurobindo Pharma Inks Licensing Deal With Merck For HIV Drug

WhalesbookOriginal source

🇪🇺Jul 25Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: GUIDE-AI – Guiding your treatment with current evidence

CORDISOriginal source

🇪🇺Jul 25Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Regenerative Medicine and Advanced Medicinal Therapeutic Products United for PhD excellence

CORDISOriginal source

🇪🇺Jul 25Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Gender, Language and Epistemicide in Reproductive Healthcare

CORDISOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Biotech companies are being reshaped by AI

SiliconANGLEOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical : Revenue and profit surged in H1 FY 2026, with strong sales, robust pipeline, and record filings

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Axsome’s Phase 3 Fibromyalgia Trial of AXS-14 Takes Shape: What Investors Should Watch

TipRanksOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy

TipRanksOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

LUCERNA Phase 3: Zolbetuximab, Pembrolizumab, and Chemotherapy in CLDN18.2/PD-L1–Positive Gastric/GEJ Cancer

OncodailyOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

FDA Votes to Reduce Restrictions on Four Peptides | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class H Revenue Breakdown – FWB:08HH

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

ETFs Investing in Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A Stocks

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Zhejiang East Asia Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:605177

TradingViewOriginal source

🌍Jul 25discoverynews.google.comTier 3 · Aggregated media

Jubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forum

MorningstarOriginal source